Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.60 |
| ▸ | LCK | P06239 | 5/20 | 0.60 |
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | CCND3 | P30281 | 2/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039916 | 1.00 | JAK3 (0.60) | JAK3LCKBTKEGFRCCND3 | |
| SCHEMBL21946882 | 1.00 | JAK3 (0.60) | JAK3LCKBTKEGFRCCND3 | |
| SCHEMBL21946316 | 1.00 | JAK3 (0.60) | JAK3LCKBTKEGFRCCND3 | |
| SCHEMBL21946354 | 0.91 | JAK3 (0.56) | JAK3LCKBTKEGFRCCND3 | |
| SCHEMBL21946309 | 0.90 | JAK3 (0.51) | JAK3LCKBTKEGFRCCND3 | |
| SCHEMBL21946794 | 0.87 | JAK3 (0.77) | JAK3LCKBTKEGFRJAK2 | |
| SCHEMBL21946884 | 0.87 | JAK3 (0.70) | JAK3LCKBTKEGFRCKS1B | |
| SCHEMBL19824686 | 0.86 | JAK3 (0.74) | JAK3LCKBTKEGFRCKS1B | |
| SCHEMBL21946362 | 0.86 | JAK3 (0.78) | JAK3LCKBTKEGFRJAK2 | |
| SCHEMBL30448209 | 0.86 | JAK3 (0.78) | JAK3LCKBTKEGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | JAK3 623/4885LCK 125/4885BTK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.